Skip to main content
Circio Holding ASA logo

Circio Holding ASA — Investor Relations & Filings

Ticker · CRNA ISIN · NO0013033795 LEI · 5967007LIEEXZXFYNS31 OL Professional, scientific and technical activities
Filings indexed 167 across all filing types
Latest filing 2025-09-05 Share Issue/Capital Cha…
Country NO Norway
Listing OL CRNA

About Circio Holding ASA

https://www.targovax.com/en/

Circio Holding ASA is a clinical-stage company developing novel medicines based on circular RNA (circRNA) and immunotherapy. The company's core focus is its proprietary circVec platform, a circular RNA expression system designed to enhance the efficacy and durability of gene and cell therapies. Circio's development pipeline is directed towards immuno-oncology, targeting difficult-to-treat solid tumors, and the application of its circRNA technology to address genetic diseases.

Recent filings

Filing Released Lang Actions
Circio Holding ASA - Conversion of Convertible Bonds and funding requested under Additional Financing Commitment from Atlas
Share Issue/Capital Change Classification · 100% confidence The document details the conversion of convertible bonds into new shares and the issuance of new convertible bonds under an existing financing agreement. This constitutes a change in the company's capital structure and share issuance. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most accurate category for announcements regarding new share issues and capital changes.
2025-09-05 English
Circio presents new circVec-AAV vectors showing up to 40x enhanced activity in first half year report webcast - Attachment: Circio 1H25 Webcast Presentation.pdf
Investor Presentation Classification · 100% confidence The document is a presentation titled '1H 2025 report and R&D update Webcast'. It contains detailed slides on R&D progress, corporate updates, financial tables (1H24, 2H24, 1H25), and strategic outlooks. It is clearly designed for investors to explain the company's technology, financial position, and future strategy. It fits the definition of an Investor Presentation (IP) as it focuses on market position, R&D pipeline, and financial performance metrics.
2025-08-28 English
Circio presents new circVec-AAV vectors showing up to 40x enhanced activity in first half year report webcast - Attachment: Circio First Half Report 2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'First half year report 2025' and contains comprehensive financial statements (Income statement, cash flow, key figures) for the 1H 2025 period. It provides a detailed management discussion and analysis of business operations, R&D progress, and strategic outlook. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-08-28 English
Circio presents new circVec-AAV vectors showing up to 40x enhanced activity in first half year report webcast
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the publication of the company's first half-year report and an accompanying webcast. It explicitly states 'Reporting material attached to this press release: Circio first half year report 2025' and 'Circio 1H25 Webcast presentation'. According to the 'Menu vs Meal' rule, since this is an announcement of reports rather than the reports themselves, it is classified as a Report Publication Announcement (RPA).
2025-08-28 English
Circio invites to first half 2025 report and R&D update webcast on 28 August
Report Publication Announcement Classification · 100% confidence The document is an invitation to a webcast regarding the upcoming release of the first half 2025 financial results and an R&D update. It is under 5,000 characters and serves as an announcement of a future event/report rather than the report itself. Therefore, it falls under the Report Publication Announcement (RPA) category.
2025-08-21 English
Circio Holding ASA Funding requested under additional financing commitment from Atlas
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a specific financing event, where the company is requesting a tranche of convertible bonds from an existing financing commitment with Atlas. This falls under the category of company fundraising and financing activities, which is explicitly defined as 'Capital/Financing Update' (CAP).
2025-08-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.